Journal
CANCER
Volume 109, Issue 1, Pages 157-163Publisher
JOHN WILEY & SONS INC
DOI: 10.1002/cncr.22385
Keywords
acute myeloid leukemia; recurrence; childhood
Categories
Funding
- NCI NIH HHS [P30 CA-21765] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER
Ask authors/readers for more resources
BACKGROUND. Outcome after recurrence of childhood acute myeloid leukemia (AML) is poor. We performed this study to identify prognostic factors for recurrence and for survival after recurrence of AML. METHODS. The clinical characteristics, biological features, treatment modalities, and outcomes of children with de novo AML who were enrolled on 3 consecutive clinical protocols from 1987 to 2002 at St. Jude Children's Research Hospital were studied. Regression modeling was used to identify prognostic factors for recurrence and for survival after recurrence. RESULTS. The outcome after recurrence was poor, with a 5-year survival estimate of only 23.3% +/- 5.7%. Multivariable analysis indicated that male sex (P = .005), autologous stem cell transplant before recurrence (P = .097), each additional month from diagnosis to recurrence (P = .041), and stem cell transplant after recurrence (P < .001) were associated with a better survival after recurrence, whereas M5 or M7 rnorphology (P = .001) were significantly predictive of a lower survival estimate after recurrence. CONCLUSION. Survival after recurrence was poor in children with AML. Novel therapies are urgently needed to prevent or to treat recurring AML. Cancer 2007;109:157-63. (c) 2006 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available